SOURCE Medicis Aesthetics Inc.
SCOTTSDALE, Ariz., June 13 /PRNewswire/
Billions of dollars are spent annually in the quest to turn back the hands of time from drugstore skin creams to the most sophisticated cosmetic procedures. According to a recent nationwide poll, this could be money well spent; 88% of Americans surveyed admitted to guessing a person's age in order to form a first impression.
So just how much does age matter? A majority of Americans taking part in this survey agreed that a youthful appearance greatly impacts confidence, happiness and professional success. And surprisingly, it's just as important for men to preserve their youthful appearance as women:
* The Key to the Corner Office: 78% feel that looking younger impacts a woman's success at work, versus 64% for men.
* The Ultimate Confidence Booster: 92% feel that looking younger affects a woman's overall confidence, versus 83% for men.
* The Secret to Happiness: 88% feel that looking younger is the key to happiness for women, versus 77% for men.
The findings were issued as part of The Restylane(R) Report on Age Impressions, an annual survey conducted by The Kelton Group. The Report, which polled 825 men and women between the ages of 21 and 55, also provides information regarding the facial features which Americans felt most revealed their age. Surprisingly, a majority of survey participants felt that smile lines and jowls were most telling of their age-even more than the forehead, or lip lines.
"Given the popularity of Botox(R), consumers have been conditioned to focus on their so-called frown lines, often at the expense of other facial areas which may show more pronounced effects of aging," said Dr. Howard Sobel, Cosmetic Dermatologic Surgeon.
"In my experience, the most common and treatable sign of aging can be the loss of volume in the lower third of the face which results in deep smile lines and downward lines at the corners of the mouth. Restoring volume in these areas with an injectable filler is a simple and effective way to take years off a patient's appearance in one office visit."
In fact, when shown pre- and post-treatment photos of patients who had their smile lines filled, in most cases, participants felt the procedures took years off the given subject's face. Overall, 76% of survey participants said they preferred to "look naturally good, fit and healthy for their age."
"The popularity of new non-surgical procedures like Botox and Restylane is owed largely to consumer demand for subtle, quick and effective options to turn back the clock. With Botox and Restylane, patients can erase the most visible signs of aging to restore a fuller more youthful contour to the face in under an hour," added Dr. Sobel.
About The Restylane Report The Restylane Report was commissioned by Medicis Aesthetics, a leading independent specialty pharmaceutical company dedicated to helping consumers attain a healthy and youthful appearance and self-image. The Company is the exclusive marketer and distributor of Restylane in the U.S. and Canada. The Report polled a nationally representative sample of 825 participants, which consisted of 635 women and 190 men during the period of January 7-10, 2005 using an e-mail invitation and online survey. To ensure a reliable and accurate representation of the U.S. population aged 21-55, quotas were set on completed interviews by three variables: age, sex, and geographic region. In this particular study, the chances are 95 in 100 that a survey result does not vary, plus or minus, by more than 3.41 percentage points from the result that would be obtained if interviews had been conducted with all persons aged 21-55 in the U.S., instead of a representative sample.
Restylane is the first dermal filler made of a crystal-clear gel called NASHA(TM) (Non-Animal Stabilized Hyaluronic Acid), and is indicated for mid to deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. Restylane uses a dual mechanism of action to correct wrinkles and folds. Upon injection, the NASHA(TM) gel adds natural volume and lift to smooth wrinkles and folds. The NASHA(TM) gel integrates into dermal tissue, then attracts and binds to water molecules to help maintain volume. Restylane is gradually degraded by the body's own mechanism. Results can be seen immediately following treatment and last about six months.
Restylane does not require any allergy or skin test prior to injection although it is contraindicated for patients with a history of allergies to the trace amounts of gram positive bacterial proteins included in the product. After your treatment, you might have some redness or swelling. This will normally last less than seven days. Sunbathing and cold outdoor activities should be avoided until any redness or swelling disappear. If you are pregnant, breastfeeding, or under 18, you shouldn't use Restylane. Restylane is a prescribed medical device, so please speak with your healthcare professional to see if it is right for you. For more information on Restylane, including complete product information, log on to http://www.RestylaneUSA.com.
About Medicis Aesthetics
Medicis Aesthetics Inc., the company that markets and sells Restylane in the U.S., is a wholly-owned subsidiary of Medicis Pharmaceutical Corporation, a leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of aesthetic, dermatological, and podiatric conditions. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis Pharmaceutical Corporation has leading branded prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin and skin-structure infections. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
Except for historical information, this press release includes "forward- looking statements" within the meaning of the Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements. This includes earnings estimates, future financial performance and other matters. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis. Any such projections or statements include the current views of Medicis with respect to future events and financial performance. No assurances can be given, however, that these events will occur or that such results will be achieved. Medicis cannot validate its assumptions of the full impact on its business of the approval of competitive generic versions of its core brands, including DYNACIN(R) Tablets and/or LOPROX(R), or any future competitive product approvals that may affect its brands. Also, there are a number of additional important factors that could cause actual results to differ materially from those projected, including the anticipated size of the markets, the availability of product supply, the receipt of required regulatory approvals, the ability to realize anticipated synergies and benefits of the Q-Med transactions, the risks and uncertainties normally incident to the pharmaceutical industry, dependence on sales of key products, the uncertainty of future financial results and fluctuations in operating results, dependence on Medicis' strategy including the uncertainty of license payments and/or other payments due from third parties, the timing and success of new product development by Medicis or third parties, product introductions, the risks of pending or future litigation, and other risks described from time to time in Medicis' SEC filings including its Annual Report on Form 10-K for the year ended June 30, 2004. There can be no assurance as to when or if any of the holders of the Notes will have the right to convert or if the Notes will be converted, and what impact the increase in the number of shares outstanding will have on its results of operations. Forward-looking statements represent the judgment of Medicis' management as of the date of this release, and Medicis disclaims any intent or obligation to update any forward-looking statements.
NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company. OMNICEF(R) is a registered trademark of Abbott Laboratories, Inc. under a license from Fujisawa Pharmaceutical Co., Ltd. RESTYLANE(R) is a registered trademark of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation. NASHA(TM) is a trademark of Q-Med AB. All other marks (or brands) and names are the property of Medicis or its Affiliates.
SOURCE Medicis Aesthetics Inc.
Disclaimer: this website is for informational purposes only, and is not intended to be a substitute for a professional medical diagnosis, opinion or suggested course of treatment. Please see your health care professional for a professional medical opinion, and refer to our Disclaimer regarding your use of this website.